Hogy Medical Co.,Ltd.
Fiscal Year Ending March 2026 Q3 Financial Results Presentation
For the cumulative third quarter of the fiscal year ending March 2026, net sales were JPY 28.71 billion (95.7% YoY), operating income was JPY 2.08 billion (61.3% YoY), and net income attributable to owners of parent was JPY 1.43 billion (52.6% YoY), all showing declines.
Key Figures
- Net Sales: JPY 28.71 billion (95.7% Year-over-Year)
- Operating Income: JPY 2.08 billion (61.3% Year-over-Year)
- Net Income Attributable to Owners of Parent: JPY 1.43 billion (52.6% Year-over-Year)
AI要約
Performance Overview
For the cumulative third quarter of the fiscal year ending March 2026, net sales were JPY 28.71 billion, down to 95.7% Year-over-Year. Operating income significantly declined to JPY 2.08 billion (61.3% YoY), and net income attributable to owners of parent dropped sharply to JPY 1.43 billion (52.6% YoY). The cost of sales ratio remained flat at 66.9%, but increased selling, general and administrative expenses along with one-time costs were primary factors in profit reduction. Sales of kit products fell to 96.7% Year-over-Year, and nonwoven fabric product sales continued to face severe conditions. The number of Opera Master contracted facilities increased by 8, reaching 248.
Business Environment and Strategy
Hospital management has not recovered to pre-COVID-19 levels, and medical service profits are deteriorating. However, discussions on sound management are progressing, triggered by the 2026 medical fee revision. In the medium to long term, hospital function reorganization is advancing, with strong expectations for structural reforms. The sales strategy prioritizes maintaining customer loyalty above all, progressing with sales reforms, product strategy, DX promotion, and procurement reforms. Overseas, a sales company was established in Malaysia to strengthen ASEAN expansion. As part of structural reforms, the company plans to relocate its headquarters in August 2025.
